Datroway Continues To Show Promising Tumor Responses As Part Of Combination Regimens In Patients With Early And Advanced Non-Small Cell Lung Cancer
RefinitivMoins d'1 minute de lecture
Daiichi Sankyo Co Ltd 4568:
DATROWAY® CONTINUES TO SHOW PROMISING TUMOR RESPONSES AS PART OF COMBINATION REGIMENS IN PATIENTS WITH EARLY AND ADVANCED NON-SMALL CELL LUNG CANCER
DAIICHI SANKYO CO LTD - PHASE 2 RESULTS SHOW POTENTIAL FOR DATROWAY PLUS DURVALUMAB
Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles